Severe Hypertriglyceridemia Clinical Trial
— ECLIPSEOfficial title:
A Randomized, Open-label, Four-Way Crossover Study to Compare the Relative Bioavailability of a Single Dose of Epanova® With Lovaza® After a Low-Fat and High-Fat Meal
Verified date | June 2015 |
Source | AstraZeneca |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The objectives of this study are to compare the relative bioavailabilities of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in plasma from a single dose of Epanova or Lovaza during periods of high- and low -fat consumption.
Status | Completed |
Enrollment | 54 |
Est. completion date | November 2010 |
Est. primary completion date | November 2010 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Men or women, aged =18. - Normal healthy volunteers based on medical history, clinical assessments, and laboratory assessments. - Body mass index 25-35 kg/m2. - Willingness to maintain current activity level. - Willingness to adhere to the Therapeutic Lifestyle Changes (TLC)diet during screening and treatment washout periods. Exclusion Criteria: - Intolerance to omega-3 fatty acids, ethyl esters, or fish. - Unable or unwilling to eat the study meals. - Use of fish oil, other EPA or DHA containing supplements, or EPA and/or DHA fortified foods within 60 days of Visit 2, or during the study. - Consumption of any fish within 7 days of Visit 2, or during the study. - Use of flaxseed, perilla seed, hemp, spirulina, or black currant oils within 7 days of Visit 2, or during the study. - History of malabsorption syndrome, Crohn's disease, acute or chronic pancreatitis, pancreatic insufficiency, small bowel resection. - Women who are pregnant, lactating, or planning to become pregnant during the study period, or women of childbearing potential who are not using acceptable contraceptive methods. A woman is considered of childbearing potential if she is not surgically sterile or is less than 1 year since last menstrual period. Examples of acceptable contraceptive methods include abstinence, intrauterine device (IUD) or double barrier method, oral or injectable contraceptives. - Recent history (past 12 months) of drug abuse or alcohol abuse. Alcohol abuse will be defined as >14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1.5 oz hard liquor). - Exposure to any investigational product, within 28 days prior to Visit 1. - Any other condition the investigator believes would interfere with the subject's ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the subject at undue risk. |
Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Radiant Research | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca | Radiant Research |
United States,
Davidson MH, Johnson J, Rooney MW, Kyle ML, Kling DF. A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a p — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | AUC(0-t): Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (the Final Time With a Concentration = LOQ) | Analyses of the outcome measures presented are for baseline-adjusted data for total (esterified and unesterfied) EPA and DHA since the presence of endogenous levels of these fatty acids would likely contribute to intra-subject variability and affect the analyses and interpretation. | Blood samples were obtained pre-dose at -1.0, -0.5, and 0 hours and after dose administration at 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 and 24 hours. | No |
Primary | AUC(Inf): Area Under the Plasma Concentration-time Curve From 0 to Infinity | Analyses of the outcome measures presented are for baseline-adjusted data for total (esterified and unesterfied) EPA and DHA since the presence of endogenous levels of these fatty acids would likely contribute to intra-subject variability and affect the analyses and interpretation. | Blood samples were obtained pre-dose at -1.0, -0.5, and 0 hours and after dose administration at 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 and 24 hours. | No |
Primary | C(Max): Maximum Plasma Concentration | Analyses of the outcome measures presented are for baseline-adjusted data for total (esterified and unesterfied) EPA and DHA since the presence of endogenous levels of these fatty acids would likely contribute to intra-subject variability and affect the analyses and interpretation. | Blood samples were obtained pre-dose at -1.0, -0.5, and 0 hours and after dose administration at 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 and 24 hours. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04541186 -
Study to Explore the Efficacy and Safety of BIO89-100 in Subjects With Severe Hypertriglyceridemia
|
Phase 2 | |
Active, not recruiting |
NCT05079919 -
A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia
|
Phase 3 | |
Completed |
NCT02189252 -
An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
|
Phase 1 | |
Active, not recruiting |
NCT01229566 -
Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia
|
Phase 3 | |
Completed |
NCT03001817 -
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
|
Phase 3 | |
Completed |
NCT03011450 -
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment
|
Phase 3 | |
Completed |
NCT05355402 -
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia
|
Phase 2 | |
Completed |
NCT04720534 -
Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia
|
Phase 2 | |
Recruiting |
NCT06347003 -
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
|
Phase 3 | |
Recruiting |
NCT06347016 -
Study of Plozasiran in Adults With Severe Hypertriglyceridemia
|
Phase 3 | |
Withdrawn |
NCT04662528 -
Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg/dL
|
Phase 3 | |
Recruiting |
NCT05852431 -
To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia
|
Phase 3 | |
Completed |
NCT01242527 -
Epanova® for Lowering Very High Triglycerides
|
Phase 2/Phase 3 | |
Completed |
NCT02944383 -
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
|
Phase 2 | |
Recruiting |
NCT05681351 -
A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
|
Phase 3 | |
Recruiting |
NCT05552326 -
A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia
|
Phase 3 | |
Withdrawn |
NCT01997268 -
The Efficacy of EPA+DHA (SC401B) for Lowering Triglyceride Levels (≥ 500 mg/dL)
|
Phase 3 |